[Form 4] Glucotrack, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Insider transactions by Director Andrew K. Balo increased his reported beneficial stake in Glucotrack, Inc. (GCTK) through several non‑derivative share grants and a stock option award. The filing records three non‑derivative stock acquisitions on 03/25/2025, 07/11/2025 and 10/03/2025 that cumulatively bring his reported direct beneficial ownership to 4,692 common shares. The filing also shows a stock option granted on 10/03/2025 to buy 4,055 shares at an exercise price of $7.4, exercisable on 10/03/2025 and expiring on 10/03/2035. The report states option vesting starts each July 1 and vests monthly over 12 months, subject to continued service. All reported figures reflect three disclosed reverse stock splits completed in 2024, 02/25/2025, and 06/13/2025.

Positive

• Reported beneficial ownership increased to 4,692 common shares after three acquisitions
• Option grant vests monthly over 12 months, aligning incentives with continued service
• Option exercisable on 10/03/2025 with a long expiration date of 10/03/2035, giving time for potential exercise

Negative

• Three reverse stock splits were implemented (May 2024, Feb 25 2025, Jun 13 2025), which often reflect prior low share price conditions
• Option exercise price is $7.4, which may be high relative to historical trading levels (not provided in this filing)

Insights

Corporate Governance Analyst

Director received staged equity and an option; vesting is service‑based and figures reflect multiple reverse splits.

The transactions show direct acquisitions totaling 4,692 common shares and a stock option on 10/03/2025 for 4,055 shares at an exercise price of $7.4. Vesting for the option series begins on July 1 of the grant year and occurs in 12 equal monthly installments ending the following June, conditioned on continued service.

Key dependencies include the director's continued service through each vesting date and the effect of three disclosed reverse stock splits on reported share counts. Monitor option exercisability on 10/03/2025 and any future filings that adjust ownership post‑exercise.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Balo Andrew K

(Last) (First) (Middle)

C/O GLUCOTRACK, INC.

301 RTE. 17 NORTH, SUITE 800

(Street)

RUTHERFORD NJ 07070

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Glucotrack, Inc. [ GCTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.001 per share	03/25/2025		A		75	A	$0	75	D
Common Stock, par value $0.001 per share	07/11/2025		A		3,332	A	$0	3,407	D
Common Stock, par value $0.001 per share	10/03/2025		A		1,285	A	$0	4,692	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$7.4	10/03/2025		A		4,055		(1)	10/03/2035	Common Stock, par value $0.001 per share	4,055	$0	4,055	D

Explanation of Responses:

1. Each option grant has a vesting commencement date of July 1 of the applicable calendar year and vests in 12 equal monthly installments over the 12-month period ending June 30 of the following year, subject to the reporting person's continued service to the Issuer through each vesting date.

Remarks:

On May 17, 2024, a 1-for-5 reverse stock split of the Issuer's common stock, par value $0.001 per share (the "Common Stock") was implemented (the "2024 Reverse Split"). On February 25, 2025, a 1-for-20 reverse stock split of the Common Stock was implemented (the "February 2025 Reverse Split"), and on June 13, 2025, a 1-for-60 reverse stock split of the Common Stock was implemented (the "June 2025 Reverse Stock Split", and together with the 2024 Reverse Split and the February 2025 Reverse Stock Split, the "Reverse Stock Splits"). All figures presented in this Form 4 reflect the Reverse Stock Splits.

	/s/ Nelson Mullins Riley & Scarborough LLP, Attorney-in-Fact	10/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Glucotrack (GCTK) director Andrew K. Balo report?

He reported three non‑derivative common stock acquisitions on 03/25/2025, 07/11/2025, and 10/03/2025, and a stock option grant on 10/03/2025 for 4,055 shares.

How many Glucotrack shares does Andrew K. Balo beneficially own after the reported transactions?

The filing shows direct beneficial ownership of 4,692 common shares following the reported transactions.

What are the terms of the stock option reported in the Form 4 for GCTK?

The option covers 4,055 shares, is exercisable on 10/03/2025, expires on 10/03/2035, and has an exercise price of $7.4.

How does vesting work for the reported option grants?

Each option grant has a vesting commencement date of July 1 of the grant year and vests in 12 equal monthly installments over the 12‑month period ending June 30 of the following year, subject to continued service.

Do the reported share figures reflect any corporate actions?

Yes. All figures in the Form 4 reflect three reverse stock splits: a 1‑for‑5 in May 2024, a 1‑for‑20 on 02/25/2025, and a 1‑for‑60 on 06/13/2025.